Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26502890 | 0.89 | CYP2D6 (0.44) | ALDH1A1LMNAMEN1MAPTKMT2A | |
| SCHEMBL13781662 | 0.86 | MEN1 (0.44) | ALDH1A1LMNAMEN1MAPTKMT2A | |
| SCHEMBL24627258 | 0.85 | ALDH1A1 (0.43) | ALDH1A1LMNAMEN1MAPTKMT2A | |
| SCHEMBL13781665 | 0.85 | ALDH1A1 (0.43) | ALDH1A1LMNAMEN1MAPTKMT2A | |
| SCHEMBL23710179 | 0.82 | ALDH1A1 (0.41) | ALDH1A1LMNAMEN1MAPTKMT2A | |
| SCHEMBL12384401 | 0.82 | ALDH1A1 (0.41) | ALDH1A1LMNAMEN1MAPTKMT2A | |
| SCHEMBL25034509 | 0.81 | CHRNB2 (0.35) | HSD11B1CYP2D6KCNH2HRH3 | |
| SCHEMBL12384390 | 0.81 | ALDH1A1 (0.48) | ALDH1A1LMNAMEN1MAPTKMT2A | |
| SCHEMBL12384428 | 0.81 | ALDH1A1 (0.40) | ALDH1A1LMNAMEN1MAPTKMT2A | |
| SCHEMBL24777816 | 0.80 | CYP2D6 (0.38) | ALDH1A1LMNAHSD11B1SMN1; SMN2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131535-A1 | ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-04-27 | — | — | US | disclosed |
| US-20180222882-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222882-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | ALDH1A1 374/4885LMNA 1681/4885MEN1 2200/4885 |
| US-20230131535-A1 | ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNK3 | ALDH1A1 1717/4885LMNA 2214/4885MEN1 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.